[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-567723-105":53,"doc-detail-567723-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","canine-allergic-dermatitis-immunotherapeutic-for-use-in-dogs-only","Canine Allergic Dermatitis Immunotherapeutic - For Use in Dogs Only","","Cytopoint is a ready-to-use, sterile liquid caninized monoclonal antibody against IL-31 for the treatment of canine allergic dermatitis, including atopic dermatitis. IL-31 is linked to pruritus, and Cytopoint binds and neutralizes soluble IL-31 to reduce itching and skin lesions. Safety is supported by a field study after subcutaneous dosing on Days 0 and 28 and by a laboratory study using monthly injections. Effectiveness includes reduced pruritus within one day and sustained benefit through day 28.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/canine-allergic-dermatitis-immunotherapeutic-for-use-in-dogs-only/567723/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/canine-allergic-dermatitis-immunotherapeutic-for-use-in-dogs-only/567723.png","ImageObject",442,249,{"name":88,"@type":89},"MrHarris58","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-23","2026-10-13",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",7,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What conditions is Cytopoint indicated to treat in dogs?","Question",{"text":109,"@type":110},"Cytopoint is shown effective for dogs against allergic dermatitis and atopic dermatitis.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"How does Cytopoint work to reduce itching and skin lesions?",{"text":114,"@type":110},"Cytopoint binds to and neutralizes soluble IL-31, inhibiting pruritus and reducing skin lesions.",{"name":116,"@type":107,"acceptedAnswer":117},"How is Cytopoint administered and how often is it repeated?",{"text":118,"@type":110},"Cytopoint is intended for subcutaneous use only. Repeat administration every 4–8 weeks as needed based on individual patients.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},567723,1792086997,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":9,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":4},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TM  \nSee productdata.aphis.usda.gov for a summary of the studies approved by the USDA for licensing this product. This package insert also contains additional information developed by the licensee.  \nCanine Allergic Dermatitis Immunotherapeutic For Use in Dogs Only  \nThis product has been shown to be e ective for the treatment of dogs against allergic dermatitis and atopic dermatitis. For more information regarding e􀀝cacyand safety data, [go to productdata.aphis.usda.gov](go to productdata.aphis.usda.gov).  \nCytopoint is a ready-to-use, sterile liquid containing a caninized monoclonal antibody (mAb) against interleukin-31 (IL-31) . IL-31 has been shown to induce pruritus in dogs in laboratory studies. Cytopoint remains in circulation for several weeks. It exerts a therapeutic e ect by binding to and neutralizing soluble IL-31, thus inhibiting pruritus and reducing skin lesions. Like other naturally occurring antibodies and antibody-antigen complexes, elimination is via normal protein degradation pathways.  \nSAFETY: A 􀀞eld safety study has demonstrated the safety of Cytopoint after subcutaneous injection under typical use conditions. In this study, dogs  \nwere administered Cytopoint (1.0-3.3 mg/kg body weight) or placebo by the subcutaneous route on Days 0 and 28. There was no clinically relevant di erence in rates of adverse events, including signs of patient discomfort on administration, between treated and placebo groups in the study of 245 canine patients (presented to veterinary hospitals and diagnosed with atopic dermatitis) . In addition, there was no clinically important di erence in clinical pathology changes between groups following either dose. A wide variety of concomitant medications were safely used, including parasiticides, antibiotics, antifungals, corticosteroids, vaccines, allergen-speci􀀞c immunotherapy, antihistamines and other antipruritics, such as oclacitinib and cyclosporine.  \nCytopoint has also been demonstrated to be safe in dogs in a laboratory  \nsafety study in which 7 consecutive monthly subcutaneous injections were administered at doses of 3.3 mg/kg or 10 mg/kg body weight (12 dogs per group) . EFFECTIVENESS: In a study of 211 canine patients presented to veterinary hospitals and diagnosed with atopic dermatitis, a single dose of Cytopoint (up to 2.0 mg/kg) or placebo was administered subcutaneously. The study demonstrated a treatment e ect for at least one month at a dose of 2.0 mg/kg. Treatment success measures were based on the owner assessment of pruritus (Visual Analog Scale; VAS) scores and veterinarian assessment of skin lesionscores (Canine Atopic Dermatitis Extent and Severity Index; CADESI-03) .1  \nIn a laboratory study using a canine model of IL-31-induced pruritus, a single dose of Cytopoint (2.0 mg/kg) or placebo was administered subcutaneously. This product has been shown to e ectively reduce IL-31-induced pruritus within one day and at day 28 in Cytopoint-treated dogs compared to placebo-treated dogs.  \nDIRECTIONS:  \nCytopoint is available in 1-mL vials in four concentrations (10, 20, 30 or 40 mg) . Administer Cytopoint at a minimum dose of 0.9 mg/lb (2 mg/kg) body weight. For convenience, the dosing tables below may be used as a guideline. Repeat administration every 4-8 weeks as needed in individual patients.  \nThe product does not contain a preservative. Each vial is for single use only. Inactivate unused contents.  \nDogs weighing \u003C 5.0 lb (\u003C2.3 kg):  \nAseptically withdraw 0.09 mL/lb (0.2 mL/kg) from a single, 10-mg (Sky) vial and administer subcutaneously. Discard any remaining product.  \nDogs weighing 5.0-40 lb (2.3-18.1 kg):  \nAseptically withdraw the full volume of the appropriate vial according to the dosage table below and administer subcutaneously.  \n\n| Dog Body\u003Cbr>Weight in\u003Cbr>Pounds | Dog Body\u003Cbr>Weight in\u003Cbr>Kilograms | Presentation |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n|  |  | 10 mg\u003Cbr>(Sky) | 20 mg\u003Cbr>(Plum) | 30 mg\u003Cbr>(Blush) | 40 mg\u003Cbr>(Navy) |\n| 5.0-10 | ","cbCaijeeWptOOiz0","https://ap.wps.com/l/cbCaijeeWptOOiz0","pdf",459906,"English","# Safety\n## Concomitant medications and adverse events\n# Effectiveness\n## Pruritus and skin lesion outcomes\n# Directions for use\n## Vials, concentrations, and dosing schedule\n## Dosing by dog body weight\n# Precautions\n## Storage and administration requirements","[{\"question\":\"What conditions is Cytopoint indicated to treat in dogs?\",\"answer\":\"Cytopoint is shown effective for dogs against allergic dermatitis and atopic dermatitis.\"},{\"question\":\"How does Cytopoint work to reduce itching and skin lesions?\",\"answer\":\"Cytopoint binds to and neutralizes soluble IL-31, inhibiting pruritus and reducing skin lesions.\"},{\"question\":\"How is Cytopoint administered and how often is it repeated?\",\"answer\":\"Cytopoint is intended for subcutaneous use only. Repeat administration every 4–8 weeks as needed based on individual patients.\"}]","Canine Allergic Dermatitis Immunotherapeutic - For Use in Dogs Only | PDF",1791867642]